Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
SAN FRANCISCO–(BUSINESS WIRE)–
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas, Nevada.
A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260505403526/en/
Media Contact
Caren Scannell
Director, Communications
[email protected]
Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
[email protected]
KEYWORDS: California Nevada United States North America
INDUSTRY KEYWORDS: Infectious Diseases Public Relations/Investor Relations Communications Clinical Trials Biotechnology Health Pharmaceutical General Health Oncology
MEDIA:
| Logo |
 |